Remogliflozin

Remogliflozin is a drug used in the treatment of Type 2 diabetes. It belongs to the class of drugs known as SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose in the urine.

Mechanism of Action

Remogliflozin works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing about 90% of the glucose in the kidneys back into the bloodstream. By inhibiting this protein, remogliflozin promotes the excretion of glucose in the urine, thereby lowering blood glucose levels.

Uses

Remogliflozin is used in the treatment of Type 2 diabetes. It is often used in combination with other diabetes medications to improve blood glucose control.

Side Effects

Common side effects of remogliflozin include urinary tract infections, increased urination, and yeast infections. More serious side effects can include kidney problems, low blood sugar (when used with other diabetes medications), and a rare but serious bacterial infection of the genital area.

Contraindications

Remogliflozin is contraindicated in patients with severe kidney impairment, end stage renal disease, or dialysis. It is also contraindicated in patients with a history of hypersensitivity to remogliflozin or any of the excipients in the product.

See Also

• Sodium-glucose transport proteins
• Type 2 diabetes
• SGLT2 inhibitors

Remogliflozin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia